People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

Getting thin to succeed in a fat-phobic society is still an understandable individual solution to a structural problem ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to ...

Thirty-nine percent of millennials and 35% of Gen Z say access to weight loss drugs would improve their job satisfaction or ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

Tack on a half-dozen zeros to your CVS receipt and you'll get a sense of the sticker shock afflicting state officials, insurers and hospitals dealing with the soaring cost of prescription drugs in ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...